Company intelligence / Profile preview

Immunovia

Ownership: Public · IMMNOV
Employees: ~100
Development stage: Commercial

Overview

Immunovia has developed and commercialized PancreaSure/IMMray™ PanCan-d, the first blood-based test for early detection of pancreatic cancer. In a study of 1,066 samples, their test detected early-stage pancreatic cancer in 78% of cases with a specificity of 94%. The product has launched commercially in the U.S., targeting high-risk individuals.

Therapeutic areas: OncologyImmunology
Modalities: Blood-based diagnostic testAntibody biomarker microarray analysis
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

IMMray PanCan-d

Commercial

Indications: Pancreatic cancer

Partnerships

Collaborations with healthcare providers, leading experts, patient advocacy groups globallyacademic roots at Lund University and CREATE Health Cancer Center

Beyond the preview

Go deeper on Immunovia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunovia.

Explore the full profile